Drug Discovery World

JANUARY 21, 2024

Proximity-inducing drugs: Using technological innovation to build the next generation of medicine Simon Bushell, SVP of Molecular Discovery of Entact Bio, has over two decades of scientific and strategic leadership experience in drug discovery. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

PLOS: DNA Science

APRIL 18, 2024

Clues to combatting a devastating disease can come from identifying people who have gene variants – mutations – that protect them, by slowing the illness or lowering the risk that it develops in the first place. That’s what the researchers wanted to find out, publishing their findings in the January 2024 Cell.

Disease 73

Disease Research DNA Therapies 73

Broad Institute

JUNE 11, 2024

#WhyIScience Q&A: A biochemist uses mass spectrometry to find proteins involved in cancer By Corie Lok June 11, 2024 Breadcrumb Home #WhyIScience Q&A: A biochemist uses mass spectrometry to find proteins involved in cancer Moe Haines talks about how his open-minded approach to science led him to pursue a career in proteomics.

Science 105

Science Pharmacy Pharmaceutical Companies DNA 105

KIF1A

JANUARY 13, 2024

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development.

DNA 105

DNA Regulations Drug Development FDA 105

Agency IQ

MARCH 29, 2024

FDA’s oncology advisory committee to consider MRD as a multiple myeloma endpoint Yesterday, the FDA announced that its Oncologic Drugs Advisory Committee would weigh in on the potential use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials. immune cells and other blood cell types) lack.

FDA 40

FDA Clinical Trials Trials Treatment 40

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

DECEMBER 14, 2020

It is considered an orphan disease for which there is no cure. billion by 2024, according to GlobalData, with the U.S. The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. . representing the largest market.

DNA 52

DNA Clinical Trials Drugs Therapies 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

MAY 23, 2024

SD: With mRNA therapy, we can combine different mRNA molecules, each one having a unique mechanism of action within a single drug product. This approach is particularly effective against diseases, such as cancer, in which attacking the disease from multiple therapeutic angles can prevent resistance development.

RNA 148

RNA Therapies Engineering Disease 148

Drug Discovery World

APRIL 25, 2024

Reece Armstrong offers an overview of cell line development and outlines the benefits the technology is bringing to biopharmaceutical developers. Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale.

Vaccine 148

Vaccine Production Pharmaceuticals Therapies 148

Agency IQ

APRIL 12, 2024

BY RACHEL COE, MSC | APR 11, 2024 1:06 PM CDT Regulatory background: Product potency and assays As defined in statute , the FDA uses the term “potency” to refer to the “specific ability or capability” of a product to “effect a given result.” Additionally, six of these comments came from the same organization (Integrated DNA Technologies).

Production 40

Production FDA Therapies Biochemical Assays 40

Agency IQ

APRIL 19, 2024

FDA advisors endorse minimal residual disease (MRD) as accelerated approval endpoint for multiple myeloma Last week, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of using minimal residual disease (MRD) as an accelerated approval endpoint for multiple myeloma.

FDA 40

FDA Disease Trials Clinical Trials 40

Codon

FEBRUARY 13, 2024

At least a million people die from drug-resistant bacterial infections every year. Nearly three million drug-resistant infections occur annually in the U.S. alone, according to the Centers for Disease Control and Prevention. This process would begin by taking a sample of bacteria from the patient and sequencing its DNA.

Therapies 138

Therapies DNA Virus Clinical Trials 138

Elrig

APRIL 29, 2024

Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

Agency IQ

FEBRUARY 2, 2024

The revisions flesh out considerations for use of biomarkers at all stages of product development and add new content on rare cancers and platform trial designs. BY KIRSTEN MESSMER, PHD, RAC, KARI OAKES | JAN 31, 2024 9:01 PM CST Regulatory Background Cancer is the second leading cause of death in the E.U. were from cancer.

Clinical Trials 40

Clinical Trials Trials Treatment Production 40